Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)

archived

This funding opportunity announcement (FOA) is a part of the National Cancer Institute (NCI) initiative the Cancer Prevention Clinical Trials Network (CP-CTNet). The CP-CTNet goals are as follows: - Design and conduct of early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis. These trials include phase 0 (micro-dosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical trials; - Characterization of the effects of these agents and interventions on their molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression, immune response) and correlation of these effects with clinical endpoints. - Development of further scientific insights into the mechanisms of cancer prevention by the agents examined, including the development of novel potential markers as determinants of response. CP-CTNet consists of two types of components: - Several CP-CTNet Sites (supported under this FOA and its predecessor RFA-CA-18-029); and - One CP-CTNet Data Management, Auditing, and Coordinating Center (covered by previously issued RFA-CA-18-030). The CP-CTNet Sites will provide scientific leadership in development and conduct of early phase cancer prevention clinical trials as well as in the management and analysis of the data.

High